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The vas deferens, a muscular conduit conveying spermatozoa from the epididymis to
the urethra, has been used as a model tissue for smooth muscle pharmacological
and physiological advancements. Many drugs, notably α-adrenergic antagonists, have
effects on contractility and thus normal ejaculation, incurring significant side effects for
patients that may interfere with compliance. A more thorough understanding of the
innervation and neurotransmitter pharmacology of the vas has indicated that this is a
highly complex structure and a model for co-transmission at the synapse. Recent models
have shown clinical scenarios that alter the vas contraction. This review covers structure,
receptors, neurotransmitters, smooth muscle physiology, and clinical implications of the
vas deferens.
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INTRODUCTION
In the treatment of male sexual disorders, focus has often been
on erectile disorders and premature ejaculation (PE), the latter
probably the most common disorder of male sexual function
(Abdel-Hamid et al., 2009). Ejaculation consists of two distinct
phases, emission and expulsion. Emission denotes the ejection
into the posterior urethra of spermatozoa mixed with products
secreted by accessory sexual glands. During the emission phase,
both epithelial secretion and smooth muscle cell contraction take
place throughout the seminal tract in a sequential manner. The
function of the vas (ductus) deferens is to convey spermatozoa
from the epididymis to the urethra. During emission, its coor-
dinated muscular contractions propel the spermatozoa toward
the urethra. However, the vas does not serve only as a conduit,
but also contributes to secretion of fluid for sperm transport
and possibly to resorption of spermatozoan remnants from the
duct lumen. Adrenergic mechanisms play a major role for vas
smooth muscle contraction, but many substances are capable of
altering its contractility by modulating neurotransmitter release
or the basal tone of the smooth muscle layers. Interference with
the contractile function by, e.g., metabolic disorders and drugs
used for lower urinary tract disorders, may lead to ejaculatory
dysfunction, and ultimately anejaculation. The mechanisms reg-
ulating the contractile behavior of the vas may therefore be of
interest as targets for drugs meant for control of ejaculation
(e.g., contraception). In addition, these mechanisms may have
general physiological/pharmacological interest since the isolated
vas deferens has proven to be one of the most useful prepara-
tions for the study of basic physiological mechanisms and the
effects of drugs. It has been used to study the electrophysiology of
the smooth muscle myocytes and the release and inactivation of
neurotransmitters, receptors and receptor-mediated mechanisms,
and signaling pathways.
The present review gives an update on some of the mecha-
nisms involved in the generation, propagation, and transduction
of signals in the vas deferens. Some examples of the clinical con-
sequences of interference with its contractile function are also
given.
GENERAL STRUCTURE OF VAS DEFERENS
The general structure and function of the vas deferens from
humans and different animal species have many similarities
(Steers, 1994; Dixon et al., 1998; Kaleczyc, 1998; Westfall and
Westfall, 2001; Burnstock and Verkhratsky, 2010). The vas is a
tubular structure consisting of a muscle coat, an inner mucosa
and an outer adventitia. The smooth muscle coat, which may
have a thickness of 1–1.5mm, consists of a circular layer sur-
rounded by inner and outer longitudinal layers. The circular
layer is the most prominent and forms a tightly wound spi-
ral, whereas the longitudinal layers are formed by muscle bun-
dles slightly helical in their arrangement. The outer longitudinal
smooth muscle cells are up to 30–40μm in length and 2–5μm
in diameter (Figure 1). Each smooth muscle cell is closely asso-
ciated with 6–12 other cells, with gaps as close as 15–20 nm
(Elbadawi and Goodman, 1980). The cells are electrically cou-
pled allowing electronic spread and depolarization to travel
from one cell to the next. This intercellular coupling can be
suppressed by heptanol (Manchanda and Venkateswarlu, 1997,
1999), believed to interact with gap junction function (Christ,
1995).
The lumen of the vas deferens is lined by columnar epithelial
cells withmicrovilli extending into the lumen (Dixon et al., 1998).
Blood supply comes from the inferior vesical artery. The vas is
innervated by autonomic postganglionic nerve fibers originating
primarily from neurons in pelvic ganglia, and to a lesser extent,
from neurons in the caudal mesenteric ganglion and sympathetic
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FIGURE 1 | Structure of the human vas deferens.
chain ganglia, and also by sensory nerve fibers arising from dor-
sal root ganglia (Kaleczyc, 1998; Kihara et al., 1998; Burnstock
and Verkhratsky, 2010). In rodents the hypogastric nerve provides
bilateral innervation to the vas, and contractile responses can
be elicited with hypogastric stimulation from either side (Kihara




Adrenergic nerves are the most common among the nerve fiber
groups supplying the mammalian vas deferens. Early studies
using fluorescence histochemistry and biochemical detection of
catecholamines have revealed numerous adrenergic nerve fibers
innervating the vas of many mammalian species including the
rat, guinea-pig, rabbit, cat, opossum, bull, and pig. The vas def-
erens of man, other primates, dog, and possibly the fox receives a
less dense adrenergic innervation than that of other species (see
overviews by Dixon et al., 1998; Kaleczyc, 1998). More recent
immunohistochemical investigations have confirmed the results
of the histochemical studies. Kaleczyc et al. (1997), showed in the
pig vas deferens, similar to what has been found in other mam-
mals, that the adrenergic nerves were distributed in the lamina
propria and throughout the circular and longitudinal muscle lay-
ers. In the lamina propria, the adrenergic axons formed a loose
network with the nerve terminals sometimes found beneath, but
never penetrating into, the epithelium. In the muscle layers, the
nerves were usually more numerous and run chiefly along the
smooth muscle cells.
There is morphological, physiological, and pharmacological
evidence that the adrenergic neurons supplying the mammalian
vas deferens can utilize adenosine triphosphate (ATP) and/or a
related purine as a possible co-transmitter with noradrenaline
(NA) (see below).
In human vas, varicose nerve terminals able to take up and
bind quinacrine have been demonstrated. These nerves may rep-
resent purinergic nerves (Alm, 1982). It may be assumed that
FIGURE 2 | Signal pathways involved in contractile activation of the
vas deferens via noradrenaline (NA; α1-Adrenoceptors) and adenosine
triphosphate (ATP; P2X receptors). SN, sympathetic neuron; PLC,
phospholipase C; DAG, diacylglycerol; PKC, protein kinase C; RhoA, ras
homolog gene family, member A; CPI-17, protein phosphatase 1 regulatory
subunit 14A; MLC, myosin light chain; IP3, inositol trisphosphate; SR,
sarcoplasmic reticulum; CIC, calcium-induced calcium release; RyR,
ryanodine receptor; BKCa, big K+ activated Ca2+ channel; L-type, L-type
voltage dependent Ca2+-channel.
these nerves also contain NA, but this does not seem to have been
established (Figure 2).
There is also evidence suggesting the coexistence of neu-
ropeptides in noradrenergic nerve fibers supplying the mam-
malian vas deferens. Although there may be species differences,
many noradrenergic nerves innervating the vas deferens mus-
cle coat also express immunoreactivity to somatostatin, Leu-
enkephalin, and neuropeptide Y (Kaleczyc, 1998; Burnstock
and Verkhratsky, 2010). The majority of adrenergic (tyrosine
hydroxylase-immunoreactive: IR) nerves supplying the muscle of
the human vas deferens (Jen et al., 1997) were shown to contain
neuropeptide Y.
Cholinergic nerves
Although the histochemical localization of acetylcholinesterase
(AChE) is thought not to be specific for cholinergic nerve fibers
(Lincoln and Burnstock, 1993), most information on choliner-
gic innervation of the vas is based on this methodology. The
general impression is that cholinergic (AChE positive or choline
acetyltransferase IR) nerve fibers supplying the mammalian vas
deferens are fewer than the adrenergic ones and are mostly con-
centrated within the lamina propria (in contrast to adrenergic
nerves that are present especially in the muscle coat). Such an
innervation pattern has been found in many mammals includ-
ing the rat, guinea-pig, dog, bull, monkey, and man (for review,
see Kaleczyc, 1998; Burnstock and Verkhratsky, 2010).
The functional significance of cholinergic input to the innerva-
tion of the vas deferens has not been established. Sjöstrand (1962)
suggested that the main action of the cholinergic innervation was
to suppress adrenergic neurotransmission. In addition to such a
function, there is some evidence that cholinergic nerves may act
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on the epithelial cells of the vas deferens (Sjöstrand, 1965), which
may be responsible for fluid resorption from the lumen or for
active secretion of certain components necessary for sperm mat-
uration. Cholinergic nerve fibers supplying the mammalian vas
deferens contain neuropeptides, particularly vasoactive intestinal
polypeptide (VIP), NPY, and/or somatostatin, as well as other
active substances such as nitric oxide synthase (Kaleczyc, 1998).
Afferent nerves
Neurons in the dorsal root ganglion contain a number of dif-
ferent substances including tachykinins, especially substance P
(SP), and calcitonin gene-related peptide (CGRP). The mam-
malian vas deferens is supplied with some CGRP- and/or SP-IR
nerve terminals that are presumed to derive from DRG (see,
Kaleczyc, 1998), which is consistent with observations of Kolbeck
and Steers (1993) in the rat that many DRG neurons project to
the vas deferens. In the pig, double-labeling immunofluorescence
has revealed almost a complete colocalization of SP and CGRP
in some nerve fibers supplying the vas deferens (Kaleczyc et al.,
1997). SP/CGRP-IR nerve terminals were located mainly in the
longitudinal muscle layer where they sometimes appeared as very
long, fine varicose fibers running parallel to the smooth mus-
cle bundles. In the lamina propria, these fibers were occasionally
discovered. CGRP-IR fibers supplying the vas deferens have been
found in some other mammals including the guinea-pig, rat, and
man. SP-IR nerves have been revealed in the mouse, guinea-pig,
cat, rabbit, and man, but are absent from the vas deferens of the
rat (see Kaleczyc, 1998; Burnstock and Verkhratsky, 2010). GCRP,
widely distributed in peripheral and central sensory afferents
throughout the body, are released in the vas deferens from var-
ious stimuli, notably capsaicin (Sheykhzade et al., 2011), which
induces GCRP release through the transient receptor potential
cation channel vanilloid subfamily member 1 (TRPV1) agonism.
As a brief review, transient receptor channels are omnipresent in
the body, typically allowing various cation passage with appropri-
ate stimuli (Nilius et al., 2007). In the vas, vanilloid are the only
subtypes to our knowledge.
Responses to nerve stimulation
Electrical field stimulation of the sympathetic nerves in the non-
human vas deferens results in a contraction with two distinct
components. The twitch or phasic component is transient, while
the secondary tonic component is maintained for the duration
of the stimulation. These biphasic responses have been found in
the guinea pig, rat, mouse, and rabbit vas deferens (Ambache
and Zar, 1971; Swedin, 1971, see review by Westfall and Westfall,
2001). Ambache and Zar (1971) suggested that the biphasic
response was due to the involvement of a second neurotrans-
mitter, and the inability of phentolamine and pretreatment with
reserpine to block the phasic portion of the neurogenic response
(Swedin, 1971) supported this suggestion. Burnstock (1972) pro-
posed that the second transmitter was ATP, and Westfall et al.
(1978) first demonstrated that stimulation of the vas deferens
results in the release of purines. Since then, neuronal release of
endogenous ATP andNA has been convincingly confirmed in sev-
eral species using various techniques (see Westfall and Westfall,
2001). In the human vas, adrenergic mechanisms were considered
primarily responsible for contraction of the smooth muscle, since
the response to nerve stimulation was more or less completely
blocked by α-adrenoceptor (AR) antagonists (Figure 2) (Anton
and McGrath, 1977; Hedlund et al., 1985; Smith and Bray, 1990;
Steers, 1994). However, Banks et al. (2006) demonstrated that
the human vas deferens smooth muscle contracts in response
to both adrenergic and purinergic agonists. They considered
the adrenergic system functionally dominant, but that puriner-
gic co-transmission was also functionally significant. While not
certain, there have been studies suggesting the presence of pace-
maker cells in the vas that initiate spontaneous contractions in a
similar manner to the Interstitial Cells of Cajal (Metzger et al.,
2008; Burnstock and Lavin, 2002). These cells may be c-kit+
interepithelial cells.
It has not been definitely established whether ATP and NA
are co-stored and released from the same vesicles or stored and
released from different vesicles. As pointed out by Knight et al.
(2003), four possible scenarios for the storage and release of these
two neurotransmitters exist: (1) ATP and NA may be stored and
released from the same vesicles, (2) ATP and NA may be stored
and released from separate vesicles, (3) ATP and NA might be
stored and released from different sets of varicosities, (4) ATP
and NA may be stored and released from the same vesicles but
in different proportions in different varicosities. The concept of
separate storage and differential release of ATP and NA seems
to have growing support (Westfall et al., 2002). Additional stud-
ies indicate that the epithelium may play a role in the regulation
of vas contractility. Ruan et al. (2008), demonstrated that exoge-
nous ATP could inhibit EFS smooth muscle contraction in an
epithelium dependent mechanism, likely through its induction
of PGE2 synthesis. This was posed to be due to P2Y receptor
activation by ATP, and calcium release from epithelium, which
leads to cAMP-dependent K+ channel activation and membrane
hyperpolarization of smooth muscle.
While ATP and NA are the primary affectors released from
nerve terminals upon stimulation, other neurotransmitters have
been posed to influence the neuromuscular relationship in the vas
deferens. Li et al. (2003, 2006) and Hu (2007) have demonstrated
that histamine coexists with NA in sympathetic nerves, is released
with nervous stimulation, and may have sympathetic affects.
Postjunctional receptor mechanisms
As indicated above, contraction of the smooth muscle myocytes
in the nonhuman vas deferens is elicited by at least two neuro-
transmitters, NA, which evokes a contraction mediated by α1-
Adrenoceptors (Minneman et al., 1988; Honner and Docherty,
1999), and ATP, which evokes a faster contraction mediated by
ligand-gated P2X1-receptors (Liang et al., 2000; Mulryan et al.,
2000). Neurotransmitter release from sympathetic varicosities
is highly intermittent (Brock and Cunnane, 1988), and non-
uniform between varicosities (Lavidis and Bennett, 1992).
Purinergic receptors
Genetic as well as pharmacological and developmental studies
provide strong evidence that P2X1 receptors, probably forming
homomeric channels, are primarily responsible for fast purinergic
transmission in the mouse vas deferens (Liang et al., 2000, 2001;
www.frontiersin.org August 2013 | Volume 4 | Article 101 | 3
Koslov and Andersson Vas deferens—an update
Mulryan et al., 2000). It has been suggested that P2X receptors
in the mouse vas deferens and other sympathetically innervated
smooth muscles exist in clusters beneath sympathetic varicosi-
ties (Barden et al., 1999). However, only a small proportion of
the P2X1-receptors located on a smooth muscle cell contribute
to spontaneous EJCs, suggesting a diffuse distribution of P2X1-
purinoceptors on the smooth muscle myocytes (Liang et al.,
2001). Immunostaining results by several groups also support the
notion that P2X1-purinoceptors in the mouse vas deferens are
diffusely distributed over the entire surface of the smooth mus-
cle cells (Vulchanova et al., 1996; Lee et al., 2000; Liang et al.,
2001). Recent analysis of the P2X1 receptor in human vas deferens
(Amobi et al., 2012) indicated P2X1-purinoceptor stimulation
elicits excitatory effects that lead to longitudinal muscle con-
traction. There was a secondary activation of 4-aminopyridine-
sensitive (KV), and iberiotoxin-sensitive (BKCa) K+ channels.
The contraction mediated by P2X1-purinoceptor stimulation was
subcontractile in circular muscle due to the ancillary activation
of BKCa channels. These differences in activation between longi-
tudinal and circular muscle were considered to have functional
implication in terms of the purinergic contribution to overall
contractile function of human vas deferens. Amobi et al. (2012)
also considered the modulatory effects of KV and BKCa channels
following P2X1-purinoceptor activation to be pivotal in provid-
ing the crucial physiological mechanism that ensures temporal
co-ordination of longitudinal and circular muscle contractility.
Interestingly, the BKCa channels have also been found to medi-
ate vas smooth muscle relaxation when stimulated with sodium
hydrosulfide (NaHS) (Li et al., 2012). Li et al. demonstrated that
NaHS induced relaxation did not involve the nitric oxide pathway,
nor transient receptor potential channels.
The most conclusive evidence to date that the P2X1-receptor
mediates the postjunctional excitatory response to ATP in the vas
deferens comes from mice lacking P2X1-receptors. The vas defer-
ens from P2X1-receptor−/− mice did not respond to exogenously
applied ATP or α,β-meATP, and these tissues lacked spontaneous
and evoked EJPs (Mulryan et al., 2000). A consequence of this
gene deletion was a 90% reduction in the fertility of male animals,
which resulted from a low sperm count in the ejaculated semen.
Thus mutant females did not become pregnant when mated with
mutant males, but normal rates of conception were observed
when they mated with wild-type or heterozygous males. The
sperm from the mutant male mice was, however, viable and able
to fertilize ova in vitro. Mulryan et al. (2000) suggested that selec-
tive pharmacological blockade of P2X1 receptors should produce
a similar effect, and might thus provide the means for developing
a non-hormonal male contraceptive pill. To this effect, sildenafil,
known to reduce vas contractility has been posed to inhibit con-
tractions by way of the purinergic receptor system (Bilge et al.,
2005). In addition, agents that potentiate the actions of ATP at
P2X1 receptors may be useful in the treatment of male infertility.
α-Adrenoceptors
The myocytes from both human and non-human vas deferens
express both α1- and α2-ARs (Hedlund et al., 1985; Salles and
Badia, 1991; Ventura and Pennefather, 1994). It has been sug-
gested that contractions of rat vas deferens smooth muscle cells to
exogenous NA or adrenaline are mediated predominantly by α1A-
ARs (Aboud et al., 1993; Honner and Docherty, 1999; Campos
et al., 2003), or the postulated α1L-AR in addition to α1A-ARs
(Ohmura et al., 1992). In a study of rat vas deferens, Honner and
Docherty (1999) found that contractions to exogenous NA were
mediated predominantly by α1A-adrenoceptors, and contractions
to endogenous NA by α1D-ARs. Cleary et al. (2004) confirmed
that the predominant α1-AR in rat vas deferens is the α1A-AR,
both in terms of ligand binding and contractions to exogenous
agonists. The α1D-AR was only detectable by ligand binding fol-
lowing chemical sympathectomy, but seemed to be involved in
NA-evoked contractions.
The human vas deferens can be contracted by NA; this effect
is mediated by α1-ARs, and the motility of the vas deferens can
be effectively inhibited by α1-AR antagonists (Holmquist et al.,
1990). In the human vas deferens, Furukawa et al. (1995) reported
that the contractile response to l-phenylephrine is mediated by
the α1A-AR subtype, a finding confirmed by several other inves-
tigators. Using RNase protection assay, in situ hybridization, and
a functional study, Moriyama et al. (1997) confirmed that both
the epididymal and pelvic portions of the human vas contained
α1A-ARs mediating the contraction of phenylephrine. This was
also found by Amobi et al. (1999a,b), who demonstrated that con-
tractions evoked by NA in both longitudinal and circular smooth
muscle from human vas deferens are mediated via activation
of α1A-ARs. However the involvement of α1A-AR variants, such
as the α1L-AR subtype may explain demonstrated differences in
effects on longitudinal and circular muscle between some α1A-AR
antagonists.
α1-AR antagonists are extensively used in the treatment of
hypertension and lower urinary tract symptoms associated with
benign prostatic hyperplasia. Among the side effects, ejaculatory
dysfunction occurs more frequently with drugs that are rela-
tively selective for α1A-ARs compared with other drugs of this
class. Sanbe et al. (2007) explored physiological contribution
of each α1-AR subtype using α1-AR subtype-selective knockout
(KO) mice (α1A-, α1B-, and α1D-AR KO mice). They found that
contractile tension of the vas deferens in response to NA was
markedly decreased in α1-AR KO mice, and this contraction was
completely abolished in α1-AR triple-KO mice. This attenuation
of contractility was also observed in the electrically stimulated vas
deferens. They concluded that α1-ARs, particularly α1A-ARs are
required for normal contractility of the vas deferens and conse-
quent sperm ejaculation as well as having a function in fertility.
These findings seem to be valid also for humans, and the func-
tional and clinical importance of the α1A-AR in the vas can be
illustrated by the effects of silodosin, which has a high selectivity
for the this receptor (Yamada et al., 2001).
Fifteen healthy male volunteers (urologists) took silodosin or
a placebo twice daily for 3 days in a randomized, double-blind
crossover design (Kobayashi et al., 2008). When on silodosin, all
the subjects had a complete lack of ejaculation. Three days after
completion of silodosin, the mean ejaculatory volume recovered
to the baseline level. There was no sperm in urine after ejaculation
under silodosin administration in any volunteer, and it was con-
cluded that the mechanism of ejaculatory dysfunction caused by
silodosin was a loss of seminal emission (anejaculation). Nagai
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et al. (2008) performed a real-time observation of ejaculation
by healthy males sing color Doppler ultrasound in three healthy
males. They concluded that the mechanism of ejaculatory
dysfunction after silodosin was intricately related to retrograde
ejaculation (retrograde inflow of seminal fluid), insufficient con-
traction of the seminal vesicles, and insufficient rhythmic con-
traction of the muscles of the pelvic floor. In a double-blind
crossover study (Shimizu et al., 2010), 50 healthy volunteer men
were randomly assigned to receive either a single dose of silodosin
or placebo with 3 days of washout before crossover. Subjects mas-
turbated 4 h after administering agents. Elevenmen overall (22%)
on silodosin administration had less than a 50% decrease from
baseline in the amount of semen. It was concluded that silodosin
may adversely affect the subjective orgasmic function by causing
an abnormal ejaculation with decreased (or no) semen discharge
and a decrease in the number of bulbocavernosus/pelvic floor
muscle contractions. Anejaculation rather that retrograde ejac-
ulation was produced. This has been confirmed in a number of
clinical studies on patients with lower urinary tract symptoms
associated with benign prostatic hyperplasia where the rate of
abnormal ejaculation has been up to 28% (Kawabe et al., 2006).
In human vas deferens, Birowo et al. (2010) found that
phophodiesterase inhibitors (PDEs), such as rolipram and RO-
1724 (PDE4), milrinone (PDE3), and sildenafil (PDE5) effectively
antagonized contraction induced by NA—this was accompanied
by an up to 2–8-fold increases in tissue cAMP concentrations.
Sildenafil produced a 12-fold increase in the cGMP concentra-
tion of the preparations. Whether or not this inhibitory action
has any effects on ejaculation in men taking, e.g., PDE5 inhibitors
remains to be established.
Other receptors
Substances other than ATP and NA can influence the contrac-
tility of the vas deferens, presumably via receptors located on
the smooth muscle. Muscarinic receptor stimulation (carbachol)
causes an M2-receptor mediated contraction of the vas deferens
(Eltze, 1994). Vasopressin contracts the human vas via stimula-
tion of V1 receptors (Andersson et al., 1988). β2-Adrenoceptors
can influence sympathetic neuroeffector transmission both pre-
junctionally, where they facilitate equally well the release of sym-
pathetic cotransmitters (see below) and postjunctionally, where
they inhibit smooth muscle contractions evoked by ATP (Todorov
et al., 2001). Other established receptors include serotonin (5HT)
have been demonstrated in several studies. Kose et al. (2012)
showed that a rat varicocele model showed decreased contractile
response to 5HT. Given that there are several other substances that
can modify the vas contractile response, including neuropeptide
Y (Torres et al., 1992), endothelin (Telemaque and d’Orleans-
Juste, 1991), vasopressin (Medina et al., 1998), and angiotensin
II (Ellis and Burnstock, 1989; Maletìnská et al., 1998), it is pos-
sible that there are still unidentified receptors in vas deferens
smooth muscle, or that the identified ones are promiscuous in
their agonist recognition.
Prejunctional receptors
In the vas deferens of humans and various animal species, it
has been amply demonstrated that a number of prejunctional
receptors can modulate the release of NA and ATP. As in many
other tissues, adrenergic nerves in the vas have prejunctional α2-
ARs which, when stimulated, reduce the release of NA. In the vas
deferens of various species, including the mouse, rat, and guinea
pig, stimulation of the prejunctional α2-ARs not only reduces the
release of NA, but that of ATP as well (Sneddon and Westfall,
1984; Driessen et al., 1993). ATP can also produce an inhibition
of transmitter release in vas deferens (Von Kugelgen et al., 1989;
Forsyth et al., 1991). In the prostatic portion of the rat vas def-
erens, endogenous ATP was found to exert a dual and opposite
modulation of NA release: an inhibition through activation of
P2Y receptors with a pharmacological profile similar to that of the
P2Y12 and P2Y13 receptors and a facilitation through activation
of P2X receptors with a pharmacological profile similar to that
of P2X1 and P2X3, or PX2/P2X3 receptors (Queiroz et al., 2003).
Some of the effects of ATP may be due to formation of adeno-
sine. Adenosine reduced the amount of nerve-stimulated 3H-NA
release, suggesting the involvement of a prejunctional P1 receptor
of the A1 type (Hedqvist and Fredholm, 1976). Adenosine A2A
receptors were found to facilitate NA release by a mechanism that
involves a protein kinase C-mediated attenuation of effects medi-
ated by presynaptic inhibitory receptors, i.e., α2-ARs, adenosine
A1 and P2Y receptors (Queiroz et al., 2003). Queiroz et al. (2004)
found that adenosine A(2B) receptors are involved in a facilitation
of NA release in the prostatic portion of rat vas deferens.
Many other prejunctional receptors in the vas deferens
from various species have been found to affect neurotransmit-
ter release including opioid, cannabinoid, bradykinin receptors
Trendelenburg et al. (2000), the β2-AR (Driessen et al., 1993,
1996; Todorov et al., 2001), the cholinergic nicotinic receptor
(Todorov et al., 1991; Von Kugelgen and Starke, 1991), the NPY
receptor Y2 (Bitran et al., 1991), GABAB receptor (Strobel et al.,
1989), histamine receptors (Zamfirova and Todorov, 1995; Poli
et al., 1994), and receptors for endothelins and natriuretic pep-
tides (Mutafova-Yambolieva and Radomirov, 1993; Mutafova-
Yambolieva et al., 1993).
Regional variation in purinergic and adrenergic responses
It is well established that various regions of the vas deferens
respond differently to nerve stimulation and exogenous agonists
(Ventura, 1998). Segments from both ends of the vas deferens
respond to ATP and NA however, segments from the prostatic end
are more responsive to ATP and segments from the epididymal
end are more responsive to NA (French and Scott, 1983; Schomig
et al., 1990; Sneddon and Machaly, 1992). The density of adren-
ergic nerves and catecholamine content is higher in the prostatic
than in the epididymal part of the vas. However, no differences
in the distribution of P2X1 receptors (Knight et al., 2003) were
demonstrated in the mouse vas, or in α1-Adrenoceptors in the
human (Hedlund et al., 1985) or rat vas (Salles and Badia, 1991;
Ventura and Pennefather, 1994). There is, however, evidence in
a rat model that the density and mRNA level of α1-receptors,
as well as maximal response to phenylephrine in the epididymal
vas may decrease with age (Yono et al., 2008). In the mouse, the
difference in response to ATP was attributed to insufficient nerve-
terminal release of ATP in the epididymal part (Knight et al.,
2003). Terradas et al. (2001) confirmed that the two portions of
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rat vas deferens differed in the postjunctional sensitivity to NA.
Western blot analysis indicated a smaller concentration of Gq/11
protein in the prostatic half, and the authors suggested that the
different sensitivity to NA could be due to the higher availability
of this sort of G protein in the epididymal portion. The functional
importance of this regional variation remains to be established.
SIGNAL PROPAGATION/SPREAD
ELECTROPHYSIOLOGY
Burnstock and Holman (1961, 1966) made the first recordings
of EJPs produced by sympathetic nerves innervating the smooth
muscle of the guinea-pig vas deferens (see, Sneddon, 2000). This
led to the identification of ATP as the mediator of EJPs in this tis-
sue. The EJPs are mediated solely by ATP acting on P2X receptors
leading to action potentials and a rapid phasic contraction, whilst
NA mediates a slower, tonic contraction which is not dependent
on membrane depolarization.
In single smooth muscle cells from the human vas, Park et al.
(2004) recorded and characterized two types of Ca2+ currents,
the L and T-type. The importance of L type Ca2+ currents for
vas contractility is well established (Ohya et al., 2001; Shishido
et al., 2009), whereas the role and action of the T-type currents are
not well defined. Park et al. (2004) also characterized two types of
K+ channel currents, namely BKCa and delayed rectifier currents.
Voltage-gated K+ currents (a fast-inactivating transient current
and a delayed rectifier current) have also been demonstrated in
rat vas deferens smooth muscle cells (Harhun et al., 2003). Their
physiological importance has not been established.
INTERCELLULAR COMMUNICATION
Paton et al. (1976), using electron microscope, was unable to
demonstrate gap junctions in the vas deferens. However, there are
reasons to believe that the smooth muscle cells of the vas are elec-
trically coupled. Neurogenic contractions such as those evoked in
the guinea pig vas deferens by stimulation of adrenergic nerves,
only a small proportion of cells are directly influenced by trans-
mitter released from the sympathetic motor innervation, because
only about a fifth of the cells receive direct innervation by close-
contact axonal varicosities (Merrillees, 1968; Bennett, 1973), and
because varicosities do not release transmitter in response to every
invasion by the axonal action potential because of the low prob-
ability of evoked transmitter release (Cunnane and Stjarne, 1984;
Brock and Cunnane, 1988). Therefore, spread and co-ordination
of excitation from the few directly activated cells to other cells
probably requires the involvement of gap junctions. As men-
tioned previously, in the smooth muscle cells of the vas deferens,
EJPs are produced following stimulations of adrenergic nerves.
EJPs are thought to reflect not just depolarization of the cell
being recorded from, but the summed activity of several cells in
the neighborhood, by virtue of intercellular electrical coupling
(Cunnane and Manchanda, 1990).
Manchanda and Venkateswarlu (1997) investigated the effects
on EJPs of heptanol, a presumptive gap junction blocking agent
(Christ, 1995), with a view to determining the influence of inter-
cellular electrical coupling on smooth muscle junction potentials.
Heptanol abolished rapidly and reversibly the EJP of the guinea
pig vas deferens. Further investigation showed that heptanol
inhibited both EJP-dependent and non EJP-dependent contrac-
tions of the vas, and that a postjunctional site of action of
heptanol, probably intercellular uncoupling of smooth muscle
cells, contributed to the inhibition of contraction (Venkateswarlu
et al., 1999).
SIGNAL TRANSDUCTION
In the vas deferens, as in other types of smooth muscle, the most
commonly used explanation for excitation–contraction coupling
in smoothmuscle cells is an increase in intracellular Ca2+ through
either L-type Ca2+ channels or the release of Ca2+ from intra-
cellular stores (Berridge, 1993, 2008). It has been shown that
blockade of L-type calcium channels by nifedipine abolishes
the purinergic component of contraction in mouse vas defer-
ens (Cleary et al., 2003), suggesting that activation of the P2X1
receptors are dependent on Ca2+ influx. Brain et al. (2003), inves-
tigating the sources and sequestration of Ca2+ to neuroeffector
Ca2+ transients in the mouse vas deferens, suggested that Ca2+
stores initially amplify and the sequester Ca2+ that enters through
P2X receptors.
The contractile response of rat vas deferens myocytes to exoge-
nous NA has been reported to be associated with the efflux of
Ca2+ from the sarcoplasmic reticulum (SR) rather than the influx
of Ca2+ via the plasmalemma. α-1-Adrenoceptors couple with
phospholipase C (PLC) (Summers and McMartin, 1993; Burt
et al., 1998) which produces inositol (1,4,5)-triphosphate (IP3)
and diacylglycerol (DAG) using phospholipids from the plasma
membrane (Berridge and Irvine, 1984). IP3 induces Ca2+ release
from the SR, allowing the activation of myosin light chain kinase
(MLCK) with ultimate phosphorylation of myosin with subse-
quent smooth muscle contraction (Somlyo and Somlyo, 1994).
Khoyi et al. (1988, 1993) suggested that the NA response relies
mainly on intracellular Ca2+ and that nifedipine-sensitive cal-
cium entry may function as a trigger for calcium-induced calcium
release (CICR) from the SR. However, in the rat vas deferens,
there is apparently little contribution to NA-induced contrac-
tion from intracellular stores, as exposing intracellular Ca2+
stores to ryanodine, cyclopiazonic acid or thapsigargin had lit-
tle effect on NA induced contraction (Amobi et al., 1999a,b).
Amobi et al. (1999a,b) suggested that the NA-induced contrac-
tion may involve an increase in the sensitivity of the contrac-
tile apparatus to Ca2+, possibly through a Rho-kinase-mediated
pathway (Büyükafar et al., 2003). In brief, the Rho is a GTPase
and its downstream protein Rho-kinase is a downstream protein
that mediates calcium sensitivity of smooth muscles via inhi-
bition of myosin phosphatase, effectively maintaining smooth
muscle contraction (Sward et al., 2000; Fukata et al., 2001);
Rho kinase (ROCK-2) is expressed in mouse vas deferens, and
inhibitors of Rho-kinase reduce contractions induced by NA
(Amobi et al., 2006), phenylephrine, ATP, and KCl (Büyükafar
et al., 2003).
There may be differences in the mechanisms for mobilizing
intracellular Ca2+ in the prostatic and epididymal parts of the rat
vas. Amobi and Smith (1999) suggested that, during stimulation
of the epididymal part, the SR functions mainly to buffer cal-
cium entering through nifedipine-sensitive voltage-gated calcium
channels. In contrast, in the prostatic part, the SR serves mainly as
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a source of calcium and contributes more to contractions evoked
by higher concentrations of the agonist.
It has been established that Ca2+ sparks are local and due
to transient Ca2+ release events from the SR through ryanodine
receptors (Jaggar et al., 2000). A spontaneous Ca2+ spark in the
superficial area activates BKCa channels nearby and inducesmem-
brane hyperpolarization, which reduces Ca2+ channel activity.
BKCa channels and ryanodine receptors may co-localize densely
at the junctional areas of plasmalemma and SR fragments, where
Ca2+ sparks occur to elicit spontaneous transient outward cur-
rents (STOCs). In single smooth muscle cells of guinea-pig vas
deferens, Ca2+ entry through voltage-dependent Ca2+ channels
in the early stages of an action potential may evoke calcium
induced calcium release from discrete subplasmalemmal Ca2+
storage sites and generate local Ca2+ transients that spread over
the cell to initiate a contraction (Imaizumi et al., 1998). In addi-
tion, the subplasmalemmal Ca2+ transients activate BK channels
nearby, which results in the activation of Ca2+-dependent K+
current, a major outward current responsible for action poten-
tial repolarization and afterhyperpolarization. These two local
Ca2+ release events, Ca2+ sparks at rest and Ca2+ transients upon
depolarization, share physiological roles to activate BK channels
and induce membrane hyperpolarization.
Ohi et al. (2001) studied local Ca2+ transient and distribu-
tion of BKCa channels and ryanodine receptors in the guinea pig
vas deferens myocytes. They found that a limited number of dis-
crete SR fragments in the subplasmalemmal area play key roles in
the control of BKCa channel activity by generating Ca2+ sparks at
rest to activate STOCs. These fragments also generate Ca2+ tran-
sients presumably triggered by sparks during an action potential
to activate a large Ca2+-dependent K+ current and also induce a
contraction. White and McGeown (2003) found in guinea pig vas
myocytes that IP3 receptors Ca2+ regulate store content andmod-
ulate Ca2+ sparks, and that blockade of these receptors increases
SR Ca2+ store content promoting Ca2+ sparks and STOC activity.
Medina et al. (2010) investigated the effects of K+ chan-
nel inhibitors on ring segments of the epididymal part of
the human vas deferens. They found that charybdotoxin and
tetraethylammonium (inhibiting non-selectively BKCa and IKCa
channels), but not iberiotoxin (inhibiting selectively BKCa chan-
nels), apamin (inhibiting SKCa channels) and glibenclamide
(inhibiting ATP sensitive K+channels) increased contraction
induced by NA and electrical field stimulation. Theys suggested
that the effects of charybdotoxin were mediated via L-type Ca2+
channels and an increase in Ca2+ influx.
MODELS OF ALTERED CONTRACTILITY
While an array of studies have attempted to understand the
physiologic nature of the vas with chemical and electrical stim-
ulation, several models have been created to understand how
different clinically applicable scenarios influence the vas. In an
attempt to understand the influence of acute ischemia, mod-
els of torsion using rats have demonstrated a decrease in con-
tractile response in the ipsilateral vas deferens (Karacay et al.,
2011) Interestingly, spontaneous hypertensive rats have shown
an INCREASE in contractile response to EFS and NA (Katsuragi
et al., 1991), and Gur et al. (2010) showed increased contrac-
tile respone to purinergic stimulation in L-NG-Nitroarginine
Methyl Ester (L-NAME) induced hypertensive rat vas deferens.
In conjuction with this study, Gur et al. (2010) also demon-
strated that rats co-treated with sildenafil and L-NAME reversed
this EFS and α-β-methylATP hypercontractile property of the
vas deferens. Additionally, a varicocele model has resulted in
a decrease vas contractile response (Ozen et al., 2007). Taken
together, alterations in vas are clinically applicable, and may
have implications for fertility, ejaculation abnormalities, and pos-
sibly vasectomy associated pain (Granitsiotis and Kirk, 2004;
Tandon and Sabanegh, 2008). Posed mechanisms for this super-
sensitivity are thought to be denervation related, and range
from increased receptor density (Hata et al., 1981), partial rest-
ing membrane potential depolarization (Fleming et al., 1973;
Fleming, 1975; Fleming and Westfall, 1975; Hershman et al.,
1992, 1993, 1995) and changes in intracellular secondary mes-
senger transduction and calcium sensitivity (Minneman et al.,
1988; Abraham et al., 2003; Quintas et al., 2005; Amobi et al.,
2006).
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